358 related articles for article (PubMed ID: 23810312)
21. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities-A Society of Interventional Oncology White Paper.
Erinjeri JP; Fine GC; Adema GJ; Ahmed M; Chapiro J; den Brok M; Duran R; Hunt SJ; Johnson DT; Ricke J; Sze DY; Toskich BB; Wood BJ; Woodrum D; Goldberg SN
Radiology; 2019 Jul; 292(1):25-34. PubMed ID: 31012818
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
[TBL] [Abstract][Full Text] [Related]
23. Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.
Wainberg ZA; Feeney K; Lee MA; Muñoz A; Gracián AC; Lonardi S; Ryoo BY; Hung A; Lin Y; Bendell J; Hecht JR
BMC Cancer; 2020 Jul; 20(1):633. PubMed ID: 32641104
[TBL] [Abstract][Full Text] [Related]
24. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
25. Value of CT-Guided Percutaneous Irreversible Electroporation Added to FOLFIRINOX Chemotherapy in Locally Advanced Pancreatic Cancer: A Post Hoc Comparison.
van Veldhuisen E; Vroomen LG; Ruarus AH; Derksen TC; Busch OR; de Jong MC; Kazemier G; Puijk RS; Sorgedrager NS; Vogel JA; Scheffer HJ; van Lienden KP; Wilmink JW; Besselink MG; Meijerink MR
J Vasc Interv Radiol; 2020 Oct; 31(10):1600-1608. PubMed ID: 32861569
[TBL] [Abstract][Full Text] [Related]
26. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
27. [The radiologist as the treating physician for cancer: interventional oncology].
van den Bosch MA; Prevoo W; van der Linden EM; Meijerink MR; van Delden OM; Mali WP; Reekers JA
Ned Tijdschr Geneeskd; 2009; 153():A532. PubMed ID: 19785894
[TBL] [Abstract][Full Text] [Related]
28. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
[TBL] [Abstract][Full Text] [Related]
29. Capecitabine: a review.
Walko CM; Lindley C
Clin Ther; 2005 Jan; 27(1):23-44. PubMed ID: 15763604
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of drug-eluting bead transarterial chemoembolization (DEB-TACE) combined with radiofrequency ablation versus DEB-TACE alone in Chinese hepatocellular carcinoma patients.
Zhu D; Yuan D; Wang Z; Chen S
Medicine (Baltimore); 2019 Jun; 98(26):e15682. PubMed ID: 31261491
[TBL] [Abstract][Full Text] [Related]
31. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
Lee JJ; Chu E
Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
[TBL] [Abstract][Full Text] [Related]
32. Editor's suggested readings in interventional oncology.
Haskal ZJ
J Vasc Interv Radiol; 2013 Aug; 24(8):1165-6. PubMed ID: 23885914
[No Abstract] [Full Text] [Related]
33. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
34. [Interventional Radiology in Oncology - Update 2021].
Henze J; Maintz D
Dtsch Med Wochenschr; 2021 Aug; 146(15):966-970. PubMed ID: 34344031
[TBL] [Abstract][Full Text] [Related]
35. The evolving role of oxaliplatin in the management of colorectal cancer.
de Gramont A; Schmoll HJ; Cervantes A; Tournigand C
Colorectal Dis; 2003 Nov; 5 Suppl 3():10-9. PubMed ID: 23573556
[TBL] [Abstract][Full Text] [Related]
36. Current status of capecitabine in the treatment of colorectal cancer.
Rothenberg ML
Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
[TBL] [Abstract][Full Text] [Related]
37. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions.
Inchingolo R; Posa A; Mariappan M; Spiliopoulos S
World J Gastroenterol; 2019 Aug; 25(32):4614-4628. PubMed ID: 31528090
[TBL] [Abstract][Full Text] [Related]
38. Current status of adjuvant therapy for colorectal cancer.
O'Connell MJ
Oncology (Williston Park); 2004 May; 18(6):751-5; discussion 755-8. PubMed ID: 15214594
[TBL] [Abstract][Full Text] [Related]
39. Which drug combination for colorectal cancer?
Doggrell SA
Expert Opin Pharmacother; 2004 Dec; 5(12):2621-4. PubMed ID: 15571479
[TBL] [Abstract][Full Text] [Related]
40. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
García-Foncillas J; Díaz-Rubio E
Clin Transl Oncol; 2010 Aug; 12(8):533-42. PubMed ID: 20709651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
